Abiopharma

🔍 Kelly Martin (Executive)

Company: Apollo Global Management, Inc. (APO)

Report Date: 2026-08-14

Detailed Transactions and Holdings:

• Sold 1,534 shares of Common Stock (Direct)
  Date: 2026-08-14 | Code: G | equity_swap_involved: 0 | shares_owned_after: 399,533.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,000 shares of Common Stock at $140.845 per share (Direct)
  Date: 2026-08-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 396,533.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-14 | Code: H | nature_of_ownership: 2025 Martin Kelly Gift Trust | shares_owned_after: 25,035.00 | Footnotes: F2

Footnotes:

• F1: Reported amount includes 304,581 vested and unvested restricted stock units ("RSUs") granted under the Apollo Global Management, Inc. 2019 Omnibus Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive, in accordance with the issuance schedule set forth in the applicable RSU award agreement, one share of common stock of the Issuer for each vested RSU. The RSUs vest in installments in accordance with the terms of the applicable RSU award agreement, provided the reporting person remains in service through the applicable vesting date.
• F2: Held by the 2025 Martin Kelly Gift Trust, a trust over which the reporting person exercises sole voting and investment control, and for which members of the reporting person's immediate family are the beneficiaries.